conduct
prospect
patientori
pilot
random
clinic
trial
rapid
multiplex
respiratori
pathogen
test
rp
test
group
vs
usual
care
usual
care
control
group
level
emerg
depart
limit
use
singleorgan
rapid
pointofcar
test
quaternari
referr
medic
center
studi
began
decemb
occur
winter
respiratori
season
interven
nonrespiratori
season
patient
elig
age
older
evalu
influenzalik
ill
ili
fever
cough
sore
throat
upper
respiratori
infect
uri
nonspecif
upper
respiratori
symptom
without
fever
patient
exclud
alreadi
antibiot
time
ed
present
english
spanishspeak
cognit
impair
legal
author
repres
expect
leav
multiplex
test
result
avail
patient
deem
elig
studi
treat
provid
approach
research
team
member
confirm
uri
ili
suspect
patient
expect
present
least
next
minut
patient
recruit
monday
friday
pm
rapid
care
main
adult
pediatr
ed
area
screen
perform
waiver
inform
consent
studi
protocol
approv
uc
davi
institut
review
board
inform
consent
patient
questionnair
administ
train
research
assist
collect
demograph
inform
medic
histori
supplementari
data
inform
patient
medic
histori
current
medic
review
electron
health
record
ehr
discuss
patient
patient
specif
ask
chronic
medic
condit
medic
condit
affect
immun
system
hiv
diabet
cancer
liver
diseas
kidney
diseas
dialysi
immunosuppress
medic
steroid
current
take
medic
subject
random
either
rapid
near
pointofcar
multirespiratori
pathogen
molecular
test
filmarray
respiratori
panel
biofir
plu
cliniciandirect
usual
care
usual
care
alon
includ
limit
test
target
influenza
andor
respiratori
syncyti
viru
rsv
pointofcar
test
quidel
flu
ab
rsv
januari
roch
liat
influenza
ab
rsv
rapid
pointofcar
test
streptococc
pharyng
acceava
strep
test
januari
roch
liat
multirespiratori
pathogen
panel
test
xtag
respiratori
viral
panel
luminex
decemb
genmark
eplex
perform
offsit
laboratori
time
weekli
schedul
daytim
batch
simpl
random
use
computergener
random
list
alloc
subject
intervent
control
arm
studi
seal
opaqu
envelop
use
blind
research
staff
alloc
written
consent
complet
clinician
patient
blind
test
done
usual
care
proceed
arm
random
patient
intervent
arm
nasopharyng
swab
specimen
collect
nurs
clinician
specimen
transport
via
tube
system
onsit
clinic
laboratori
upstair
filmarray
respiratori
panel
perform
real
time
goal
result
report
ehr
within
hour
clinician
inform
result
patient
rapid
molecular
test
would
return
patient
ehr
receiv
automat
inbasket
messag
ehr
well
notif
research
coordin
research
assist
result
back
followup
treatment
outcom
data
abstract
subject
ehr
train
research
staff
member
abstract
data
includ
medic
histori
clinic
sign
symptom
demograph
lab
radiolog
result
medic
includ
asthma
diabet
chemotherapi
immunosuppress
antibiot
antivir
medic
edhospit
cours
length
edhospit
stay
clinician
diagnos
index
encount
limit
review
subsequ
encount
identifi
death
revisit
ed
studi
site
similar
complaint
return
visit
record
categor
either
respiratori
ill
nonrespiratori
ill
accord
primari
diagnos
encount
case
patient
return
ed
left
treat
chief
complaint
use
instead
diagnosi
chest
xray
result
review
clinic
investig
lsm
identifi
patient
imag
consist
bacteri
pneumonia
viral
pattern
ill
primari
outcom
antibiot
administr
prescript
ed
emerg
medicin
clinician
secondari
outcom
includ
proport
patient
respiratori
pathogen
identifi
filmarray
respiratori
panel
test
upper
respiratori
pathogen
diagnost
test
order
physician
proport
patient
laboratoryconfirm
influenza
diagnosi
proport
patient
receiv
appropri
antiinfluenza
treatment
prescript
ed
emerg
medicin
clinician
composit
rate
antiinfluenza
treatment
posit
patient
nonus
antiinfluenza
treatment
neg
patient
proport
patient
discharg
home
ed
vs
hospit
admiss
proport
patient
allcaus
respiratori
repeat
ed
visit
hospit
icu
admiss
death
within
day
clinician
adher
guidelin
treatment
patient
influenza
recommend
use
antivir
length
ed
stay
length
hospit
stay
time
influenza
test
result
time
respiratori
pathogen
test
result
summar
data
standard
descript
statist
continu
variabl
mean
standard
deviat
sd
median
rang
categor
variabl
frequenc
percentag
analyz
equal
proport
binari
outcom
chisquar
fisher
exact
test
appropri
eg
cell
count
report
p
valu
unadjust
multipl
test
also
comput
differ
event
rate
ie
proport
associ
confid
interv
ci
continu
outcom
wilcoxon
test
use
comparison
also
perform
post
hoc
stratifi
analysi
antibiot
use
primari
outcom
antivir
use
discharg
statu
base
patient
age
eg
adult
vs
pediatr
exploratori
purpos
analyz
data
base
modifi
intenttotreat
principl
analyz
patient
random
exclud
earli
dropout
outcom
data
unavail
use
sa
version
sa
institut
cari
nc
usa
data
analysi
studi
initi
decemb
target
enrol
particip
month
base
power
calcul
patient
arm
would
power
detect
differ
antibiot
prescript
arm
studi
stop
april
month
due
budgetari
constraint
studi
enrol
patient
random
intervent
rp
test
group
random
usual
care
control
group
figur
statist
signific
differ
age
race
exist
chronic
medic
condit
group
complet
baselin
characterist
studi
particip
summar
tabl
rp
test
group
patient
virus
detect
report
ed
visit
addit
rp
patient
posit
viru
result
report
ed
visit
tabl
control
group
patient
viru
detect
report
exist
singleorgan
test
ed
visit
addit
patient
viru
detect
via
offsit
laboratori
multirespiratori
pathogen
panel
ed
visit
result
rapid
rp
test
avail
hour
averag
tabl
primari
secondari
outcom
result
shown
tabl
twenti
patient
receiv
antibiot
rp
test
group
includ
patient
viru
detect
wherea
patient
receiv
antibiot
usual
care
control
arm
includ
patient
viru
detect
antibiot
treatment
differ
ci
p
chisquarefish
exact
test
rp
test
group
patient
receiv
antibiot
despit
viru
detect
either
concomit
bacteri
infect
diagnos
clinic
discharg
rp
result
avail
statist
signific
differ
antivir
use
group
p
test
rp
test
group
patient
rapid
singleorgan
test
perform
influenza
addit
intervent
rp
test
control
patient
rapid
singleorgan
test
perform
ed
patient
rapid
influenza
test
alon
patient
rapid
influenza
rapid
rsv
test
offsit
respiratori
panel
perform
result
deliv
ed
visit
total
control
patient
respiratori
viral
test
signific
differ
length
ed
stay
disposit
ed
hospit
stay
among
admit
patient
group
seven
control
patient
admit
icu
vs
rp
test
group
supplementari
tabl
provid
clinic
data
control
patient
post
hoc
analysi
stratifi
age
pediatr
patient
receiv
antibiot
rp
test
group
vs
usual
care
control
group
antibiot
treatment
differ
ci
p
chisquarefish
exact
test
tabl
outcom
differ
group
post
hoc
stratifi
age
analysi
tabl
larg
molecular
panel
capabl
detect
respiratori
virus
simultan
avail
year
util
detect
noninfluenza
nonrsv
virus
outpati
debat
result
delay
therapi
exist
meanwhil
diagnost
advanc
made
possibl
get
result
within
hour
reduc
unnecessari
antibiot
use
becom
nation
prioriti
filmarray
respiratori
panel
provid
result
differ
respiratori
pathogen
approxim
hour
sensit
specif
howev
larg
multipathogen
test
expens
target
pointofcar
test
clinic
util
rigor
evalu
especi
ed
result
payer
current
move
limit
util
reimburs
larg
multipathogen
panel
favor
target
influenza
andor
rsv
test
evid
gap
util
reimburs
uncertainti
creat
challeng
clinician
laboratori
hospit
justifi
cost
instrument
test
lack
guidanc
regard
optim
use
hypothes
rapid
multirespiratori
pathogen
test
result
report
ed
visit
could
alter
treatment
earli
phase
patient
care
potenti
impact
patient
health
care
outcom
thu
conduct
random
clinic
trial
filmarray
rp
vs
usual
care
ed
patient
sign
symptom
upper
respiratori
infect
influenzalik
ill
primari
outcom
antibiot
prescript
trial
stop
month
reach
prespecifi
sampl
size
due
dwindl
fund
slow
enrol
howev
trend
toward
decreas
antibiot
use
rp
test
differ
p
chisquarefish
exact
test
larger
pediatr
patient
differ
p
agestratifi
post
hoc
analysi
suggest
potenti
benefit
increas
rapid
rp
test
ed
patient
antivir
prescript
ie
oseltamivir
significantli
affect
despit
increas
viral
vs
influenza
detect
vs
perhap
due
lack
guidanc
regard
antivir
use
studi
secondari
outcom
ed
disposit
return
visit
death
differ
group
thu
main
effect
rapid
rp
test
studi
increas
proport
patient
labconfirm
viral
detect
clinic
decisionmak
reduc
antibiot
prescript
onethird
unknown
similar
benefit
could
achiev
target
test
influenza
andor
rsv
antimicrobi
stewardship
alon
howev
suggest
influenza
test
alon
may
suffici
costeffect
appli
outpati
given
virus
specif
treatment
time
potenti
benefit
rapid
rp
test
infect
prevent
patient
satisfact
investig
rel
studi
investig
effect
larg
respiratori
panel
outcom
prior
random
control
trial
perform
us
ed
patient
knowledg
recent
trial
argentinian
ed
found
reduc
antibiot
antivir
initi
patient
receiv
filmarray
assay
vs
standard
test
studi
better
power
patient
studi
may
generaliz
unit
state
empir
treatment
without
test
common
countri
retrospect
analysi
roger
et
al
biofir
filmarray
associ
decreas
durat
antibiot
use
length
hospit
stay
length
isol
children
admit
hospit
arti
futur
investig
target
use
rapid
multiplex
test
ed
could
yield
promis
result
addit
research
need
determin
patient
would
benefit
test
exampl
xu
et
al
show
filmarray
could
costeffect
replac
offsit
direct
fluoresc
antibodi
test
pediatr
ed
patient
recent
random
control
trial
unit
kingdom
found
increas
patient
short
cours
antibiot
reduct
length
stay
patient
rapid
rp
test
see
differ
overal
proport
antibiot
treatment
compar
control
arm
howev
studi
done
outsid
unit
state
includ
patient
outsid
ed
result
may
directli
compar
studi
patient
came
heterogen
ed
patient
popul
includ
wide
rang
individu
arti
anywher
provid
differenti
diagnosi
hindsight
may
ideal
popul
clinician
would
necessarili
order
rapid
multiplex
test
patient
may
less
like
modifi
behavior
respons
result
howev
high
rate
chest
xray
test
studi
studi
arm
suggest
provid
least
consid
respiratori
ill
patient
may
habit
reli
viral
test
clinic
decisionmak
anoth
interpret
result
multiplex
test
well
identifi
influenza
uricaus
virus
ed
implement
alon
suffici
significantli
influenc
clinician
decisionmak
patient
outcom
exampl
influenza
test
alon
may
enough
clinic
decisionmak
influenza
season
like
thought
comprehens
stewardship
program
around
rapid
diagnost
could
requir
lead
meaning
chang
outcom
also
possibl
deploy
rapid
diagnost
tool
would
lead
signific
chang
appli
area
higher
baselin
antibiot
prescript
rate
urgent
care
set
shorten
turnaround
time
tat
biofir
filmarray
respiratori
panel
might
also
necessari
test
effect
ed
set
although
current
test
much
faster
offsit
respiratori
viral
panel
use
facil
still
fast
enough
match
fastpac
workflow
mani
ed
andrew
et
al
also
encount
problem
tat
pointofcar
poc
implement
filmarray
howev
problem
mainli
attribut
staff
avail
run
test
consent
subject
filmarray
report
run
minut
poc
set
filmarray
could
implement
ed
poc
test
way
would
fit
seamlessli
ed
workflow
tat
may
minim
assay
may
seen
promis
result
demonstr
post
hoc
analysi
brendish
et
al
random
control
trial
uk
signific
improv
outcom
includ
antibiot
treatment
durat
antibiot
seen
patient
virusposit
rp
test
achiev
tat
hour
vs
hour
regard
encourag
see
newer
poc
nucleic
acid
amplif
test
influenza
rsv
come
market
shorter
tat
order
minut
also
possibl
pathogen
detect
provid
suffici
inform
clinician
reduc
antibiot
recent
fdaclear
biofir
filmarray
pneumonia
panel
identifi
wider
rang
respiratori
bacteria
virus
depend
tat
abil
fit
ed
workflow
test
could
help
reduc
diagnost
uncertainti
lower
respiratori
tract
infect
also
part
differenti
diagnosi
howev
detect
pathogen
may
answer
result
recent
palmetto
gba
decis
medicar
longer
provid
coverag
larg
multiplex
diagnost
viral
panel
biofir
filmarray
outpati
unless
polici
chang
futur
decis
cover
respiratori
pathogen
target
limit
use
infecti
diseas
clinician
except
case
urgent
care
ed
inpati
set
highlight
import
implement
evalu
diagnost
test
context
valuebas
health
care
system
simpli
provid
test
result
without
consider
behavior
aspect
antimicrobi
prescrib
may
result
lack
clinic
util
test
could
benefici
pair
behavior
econom
strategi
part
comprehens
stewardship
program
reduc
inappropri
antibiot
use
studi
limit
small
sampl
size
like
provid
enough
power
see
signific
differ
outcom
suggest
wide
confid
interv
observ
subject
select
base
symptom
rather
clinic
decis
order
multiplex
test
turn
led
heterogen
subject
popul
mani
might
expect
benefit
viral
test
locat
specif
target
popul
rapid
multiplex
test
ed
may
necessari
signific
differ
outcom
final
influenza
season
activ
undertaken
reduc
inappropri
prescrib
viral
respiratori
infect
otherwis
healthi
patient
use
patient
provid
educ
provid
public
commit
reduc
inappropri
antibiot
use
peer
comparison
data
thu
alreadi
low
prescrib
rate
may
reduc
may
compound
loss
power
underenrol
decreas
differ
rp
usual
care
group
anticip
power
studi
also
analyz
costeffect
research
need
determin
multiplex
test
econom
feasibl
ed
final
like
use
comprehens
stewardship
strategi
guidelin
could
improv
effect
beyond
simpl
introduct
rapid
diagnost
test
also
sever
strength
studi
includ
rigor
experiment
studi
design
rel
rapid
tat
given
current
state
art
gener
preliminari
data
futur
rigor
multicent
clinic
trial
evalu
implement
rapid
respiratori
panel
ed
acut
care
set
summari
random
control
trial
aim
evalu
impact
rapid
multiplex
respiratori
panel
test
ed
patient
concern
acut
respiratori
tract
infect
although
studi
lack
power
see
signific
differ
outcom
observ
trend
decreas
antibiot
use
receiv
multiplex
test
vs
standard
care
evalu
rapid
multiplex
test
ed
could
see
chang
outcom
limit
studi
address
mainli
includ
identifi
right
patient
popul
test
alter
patient
care
vs
target
test
test
focus
implement
comprehens
stewardship
strategi
alongsid
diagnost
tool
ensur
test
util
appropri
effect
